Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial

Christopher P. Cannon; Vlado Perkovic; Rajiv Agarwal; James Baldassarre; George L. Bakris; Barry M. Brenner; David Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Hiddo J. Lambers Heerspink; Meg Jardine; Adeera Levin; Jing-Wei Li; Bruce Neal; Carol Pollock; David Wheeler; Hong Zhang; Bernard Zinman; Kenneth W. Mahaffey

Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial

Christopher P. Cannon, Vlado Perkovic, Rajiv Agarwal, James Baldassarre, George L. Bakris, Barry M. Brenner, David Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J. Lambers Heerspink, Meg Jardine, Adeera Levin, Jing-Wei Li, Bruce Neal, Carol Pollock, David Wheeler, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey

Onderzoeksoutput: Meeting Abstract › Academic

Originele taal-2	English
Aantal pagina's	3
Tijdschrift	Circulation
Volume	140
Status	Published - 19-nov.-2019
Evenement	Scientific Sessions of the American-Heart-Association - Philadelphia, Panama Duur: 16-nov.-2019 → 18-nov.-2019

Handle.net

Permanente koppeling

Citeer dit

Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G. L., Brenner, B. M., Charytan, D., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., Jardine, M., Levin, A., Li, J.-W., Neal, B., Pollock, C., Wheeler, D., Zhang, H., Zinman, B., & Mahaffey, K. W. (2019). Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial. Circulation, 140.

@article{94145a9dc8594389984cccd7ba8e619b,

title = "Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial",

author = "Cannon, {Christopher P.} and Vlado Perkovic and Rajiv Agarwal and James Baldassarre and Bakris, {George L.} and Brenner, {Barry M.} and David Charytan and {de Zeeuw}, Dick and Robert Edwards and Tom Greene and Heerspink, {Hiddo J. Lambers} and Meg Jardine and Adeera Levin and Jing-Wei Li and Bruce Neal and Carol Pollock and David Wheeler and Hong Zhang and Bernard Zinman and Mahaffey, {Kenneth W.}",

year = "2019",

month = nov,

day = "19",

language = "English",

volume = "140",

journal = "Circulation",

issn = "0009-7322",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

note = "Scientific Sessions of the American-Heart-Association ; Conference date: 16-11-2019 Through 18-11-2019",

}

Cannon, CP, Perkovic, V, Agarwal, R, Baldassarre, J, Bakris, GL, Brenner, BM, Charytan, D, de Zeeuw, D, Edwards, R, Greene, T, Heerspink, HJL, Jardine, M, Levin, A, Li, J-W, Neal, B, Pollock, C, Wheeler, D, Zhang, H, Zinman, B & Mahaffey, KW 2019, 'Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial', Circulation, vol. 140.

TY - JOUR

T1 - Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%

T2 - Scientific Sessions of the American-Heart-Association

AU - Cannon, Christopher P.

AU - Perkovic, Vlado

AU - Agarwal, Rajiv

AU - Baldassarre, James

AU - Bakris, George L.

AU - Brenner, Barry M.

AU - Charytan, David

AU - de Zeeuw, Dick

AU - Edwards, Robert

AU - Greene, Tom

AU - Heerspink, Hiddo J. Lambers

AU - Jardine, Meg

AU - Levin, Adeera

AU - Li, Jing-Wei

AU - Neal, Bruce

AU - Pollock, Carol

AU - Wheeler, David

AU - Zhang, Hong

AU - Zinman, Bernard

AU - Mahaffey, Kenneth W.

PY - 2019/11/19

Y1 - 2019/11/19

M3 - Meeting Abstract

SN - 0009-7322

VL - 140

JO - Circulation

JF - Circulation

Y2 - 16 November 2019 through 18 November 2019

ER -